Latest & greatest articles for warfarin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on warfarin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on warfarin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for warfarin

301. Efficacy of fixed minidose warfarin prophylaxis in total hip replacement. (Full text)

Efficacy of fixed minidose warfarin prophylaxis in total hip replacement. To determine whether a small fixed perioperative dose of warfarin would prevent deep vein thrombosis after total hip replacement.Prospective, randomised, double blind placebo controlled trial.Winford Orthopaedic Hospital, Bristol.148 patients having primary total hip replacement.Warfarin 1 mg given daily for one week before and three weeks after surgery.Deep vein thrombosis diagnosed by the iodine-125 labelled fibrinogen (...) uptake method.Deep vein thrombosis occurred in 25 (34%) of the patients given warfarin and 19 (26%) of the controls (difference 8%; 95% confidence interval -6.8% to 22.8%).Fixed minidose warfarin does not prevent deep vein thrombosis after total hip replacement.

1991 BMJ PubMed

302. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. (PubMed)

The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. Nonrheumatic atrial fibrillation increases the risk of stroke, presumably from atrial thromboemboli. There is uncertainty about the efficacy and risks of long-term warfarin therapy to prevent stroke.We conducted an unblinded, randomized, controlled trial of long-term, low-dose warfarin therapy (target prothrombin (...) -time ratio, 1.2 to 1.5) in patients with nonrheumatic atrial fibrillation. The control group was not given warfarin but could choose to take aspirin.A total of 420 patients entered the trial (212 in the warfarin group and 208 in the control group) and were followed for an average of 2.2 years. Prothrombin times in the warfarin group were in the target range 83 percent of the time. Only 10 percent of the patients assigned to receive warfarin discontinued the drug permanently. There were 2 strokes

1990 NEJM

303. The effect of warfarin on mortality and reinfarction after myocardial infarction. (PubMed)

The effect of warfarin on mortality and reinfarction after myocardial infarction. The use of oral anticoagulation in the long-term treatment of survivors of acute myocardial infarction has been highly controversial. We therefore randomly assigned 1214 patients who had recovered from acute myocardial infarction (mean interval from the onset of symptoms to randomization, 27 days) to treatment with warfarin (607 patients) or placebo (607 patients) for an average of 37 months (range, 24 to 63 (...) ).At the end of the treatment period, there had been 123 deaths in the placebo group and 94 in the warfarin group--a reduction in risk of 24 percent (95 percent confidence interval, 4 to 44 percent; P = 0.027). A total of 124 patients in the placebo group had reinfarctions, as compared with 82 in the warfarin group--a reduction of 34 percent (95 percent confidence interval, 19 to 54 percent; P = 0.0007). Furthermore, we observed a reduction of 55 percent (95 percent confidence interval, 30 to 77 percent

1990 NEJM

304. Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin. (Full text)

Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin. To investigate the suitability of treatment with low dose aspirin or warfarin, or both, as possible prophylaxis against cardiovascular disease by determining the effect on gastric mucosal bleeding.Randomised crossover trial.Academic department of therapeutics.Twenty healthy male volunteers aged 19-22.On separate occasions and in randomised order all subjects received aspirin 75 mg, warfarin, or aspirin 75 mg combined (...) with warfarin. Each treatment was given for 12 days or (when warfarin was used) for longer if necessary until the international normalised ratio of the prothrombin time was stable at 1.4-1.6.Loss of blood over 10 minutes into gastric washings.Bleeding over 10 minutes into gastric washings under baseline conditions and after five days, and at end of each regimen of treatment. Aspirin 75 mg increased bleeding from 0.60 (95% confidence interval 0.36 to 0.99) microliters/10 minutes to 1.26 (0.71 to 2.25

1989 BMJ PubMed

305. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. (PubMed)

Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. From November, 1985, to June, 1988, 1007 outpatients with chronic non-rheumatic atrial fibrillation (AF) entered a randomised trial; 335 received anticoagulation with warfarin openly, and in a double-blind study 336 received aspirin 75 mg once daily and 336 placebo. Each patient was followed up for 2 years or until termination (...) of the trial. The primary endpoint was a thromboembolic complication (stroke, transient cerebral ischaemic attack, or embolic complications to the viscera and extremities). The secondary endpoint was death. The incidence of thromboembolic complications and vascular mortality were significantly lower in the warfarin group than in the aspirin and placebo groups, which did not differ significantly. 5 patients on warfarin had thromboembolic complications compared with 20 patients on aspirin and 21 on placebo

1989 Lancet

306. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. (PubMed)

Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Two anticoagulant regimens, similar except for the timing of warfarin therapy, were compared in patients with clinically submassive venous thromboembolism (VTE). Warfarin was begun after 7 days of continuous intravenous heparin infusion in group L (127 patients) or within 3 days (average 1 day) of starting heparin in group S (139 patients), with similar outcomes. The frequency of symptomatic (...) treatment group. Early warfarin treatment significantly shortened hospital stay by an average of 3.9 days (30%) in patients admitted solely because of VTE.

1986 Lancet

307. Two-step warfarin therapy. Prevention of postoperative venous thrombosis without excessive bleeding. (PubMed)

Two-step warfarin therapy. Prevention of postoperative venous thrombosis without excessive bleeding. In a randomized, prospective trial of 100 patients, we have studied the safety and efficacy of warfarin sodium in comparison with that of dextran 40 in the prevention of venous thrombosis in patients at high risk for deep vein thrombosis after elective total hip or knee replacement. Warfarin was given in a new two-step regimen designed to avoid bleeding complications while still preventing (...) venous thrombosis. A low dose of warfarin was started ten to 14 days preoperatively, and the prothrombin time was regulated to between 1.5 and 3 seconds longer than control at the time of surgery; immediately after surgery, the dose was increased to prolong the prothrombin time to 1.5 times control. The overall incidence of venous thrombosis as documented by venography was less in the 53 patients treated with warfarin than in the 37 treated with dextran (21% v 51%), as was the incidence of thrombi

1983 JAMA

308. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. (PubMed)

Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. Previously, we compared fixed low doses of heparin with adjusted doses of warfarin for the long-term treatment of venous thrombosis; in that study low-dose heparin was ineffective in preventing recurrence in patients with proximal-vein thrombosis. We have now completed a randomized trial comparing adjusted doses of heparin and of warfarin for prevention of recurrent venous thromboembolism (...) in patients with proximal-vein thrombosis. One hundred six consecutive patients with acute proximal-vein thrombosis confirmed by venography were treated with intravenous heparin and then randomized to secondary prophylaxis. Two of 53 patients receiving heparin, as compared with one of 53 receiving warfarin, had new episodes of objectively documented venous thromboembolism. Nine patients taking warfarin had bleeding complications (which were major in three patients), as compared with one patient taking

1982 NEJM

309. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. (PubMed)

Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. In a controlled, randomized study, survival of patients with small cell carcinoma of the lung (SCCL) was prolonged on addition of warfarin sodium to combination chemotherapy plus radiation therapy. Median survival for 25 control patients was 24 weeks and for 25 warfarin-treated patients was 50 weeks. This difference could not be accounted for by differences between groups in performance (...) status, extent of disease, age, or sex. The survival advantage associated with warfarin administration was observed both for patients with extensive disease and for those who failed to achieve complete or partial remission. The warfarin-treated group also demonstrated a significantly increased time to first evidence of disease progression. These results suggest that warfarin may be useful in the treatment of SCCL and also support the hypothesis that the blood coagulation mechanism may be involved

1981 JAMA

310. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. (PubMed)

Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. Acute deep-vein thrombosis is usually treated with intravenous heparin for a number of days, then with oral anticoagulants for weeks to months. We have compared adjusted-dose warfarin sodium with fixed low-dose subcutaneous heparin in the prevention of recurrent deep-vein thrombosis. Sixty-eight patients with acute deep-vein thrombosis confirmed by venography were treated with intravenous heparin (...) and then randomized to secondary prophylaxis. Nine of 35 patients receiving subcutaneous heparin, but none of 33 receiving warfarin sodium, had new episodes of objectively documented venous thromboembolism (P = 0.001). Seven patients on warfarin sodium experienced bleeding complications (of which four were major), as compared with no patients receiving subcutaneous heparin (P less than 0.005). Thus, adjusted-dose warfarin sodium is more effective than low-dose subcutaneous heparin in preventing recurrent venous

1979 NEJM

311. Warfarin sodium in prevention of deep venous thrombosis and pulmonary embolism in patients with fractured neck of femur. (PubMed)

Warfarin sodium in prevention of deep venous thrombosis and pulmonary embolism in patients with fractured neck of femur. In a prospective controlled randomised trial, the prophylactic value of warfarin sodium (in doses aimed at maintaining a "Thrombotest" value of 10% and given from the day of admission until independent mobility had been achieved or for 3 mo, whichever was the sooner) was assessed in 160 elderly patients who had sustained a fracture of the femoral neck. Treatment significantly

1976 Lancet

312. Interaction of sodium warfarin and rifampin. Studies in man. (PubMed)

Interaction of sodium warfarin and rifampin. Studies in man. 4852505 1974 11 07 2013 11 21 0003-4819 81 3 1974 Sep Annals of internal medicine Ann. Intern. Med. Interaction of sodium warfarin and rifampin. Studies in man. 337-40 O'Reilly R A RA eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial United States Ann Intern Med 0372351 0003-4819 5Q7ZVV76EI Warfarin VJT6J7R4TR Rifampin AIM IM Administration, Oral Adult Drug Antagonism Humans Injections, Intravenous Male (...) Middle Aged Prothrombin Time Rifampin pharmacology Warfarin administration & dosage antagonists & inhibitors blood metabolism 1974 9 1 1974 9 1 0 1 1974 9 1 0 0 ppublish 4852505

1974 Annals of Internal Medicine

313. Prothrombin levels maintained with meprobamate and warfarin. A controlled study. (PubMed)

Prothrombin levels maintained with meprobamate and warfarin. A controlled study. 4623950 1972 07 29 2016 10 17 0098-7484 220 11 1972 Jun 12 JAMA JAMA Prothrombin levels maintained with meprobamate and warfarin. A controlled study. 1460-2 Gould L L Michael A A Fisch S S Gomprecht R F RF eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial United States JAMA 7501160 0098-7484 0 Placebos 5Q7ZVV76EI Warfarin 9001-26-7 Prothrombin 9I7LNY769Q Meprobamate AIM IM Adult Aged (...) Animals Clinical Trials as Topic Dogs Drug Interactions Female Humans Long-Term Care Male Meprobamate administration & dosage metabolism therapeutic use Microsomes, Liver enzymology Middle Aged Placebos Prothrombin Prothrombin Time Rats Time Factors Warfarin administration & dosage metabolism therapeutic use 1972 6 12 1972 6 12 0 1 1972 6 12 0 0 ppublish 4623950

1972 JAMA

314. Prevention of venous thromboembolism following total hip replacement. Warfarin vs dextran 40. (PubMed)

Prevention of venous thromboembolism following total hip replacement. Warfarin vs dextran 40. 5067322 1972 07 08 2016 11 22 0098-7484 220 10 1972 Jun 05 JAMA JAMA Prevention of venous thromboembolism following total hip replacement. Warfarin vs dextran 40. 1319-22 Harris W H WH Salzman E W EW DeSanctis R W RW Coutts R D RD eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial United States JAMA 7501160 0098-7484 0 Dextrans 5Q7ZVV76EI Warfarin 9NEZ333N27 Sodium AIM IM (...) Adult Age Factors Aged Dextrans administration & dosage Evaluation Studies as Topic Female Hematocrit Hip surgery Hip Joint Hospitalization Humans Injections, Intramuscular Joint Prosthesis Length of Stay Male Middle Aged Postoperative Complications Prospective Studies Prothrombin Time Sodium administration & dosage Thrombophlebitis prevention & control Warfarin administration & dosage adverse effects 1972 6 5 1972 6 5 0 1 1972 6 5 0 0 ppublish 5067322

1972 JAMA